Updated international consensus report on the investigation and management of primary immune thrombocytopenia.
暂无分享,去创建一个
J. Bussel | B. Chong | Y. Tomiyama | F. Rodeghiero | S. Pavord | A. Newland | M. Scully | M. Michel | B. Godeau | D. Kuter | C. Kruse | F. Zaja | R. Wong | W. Ghanima | D. Arnold | J. Grainger | T. Gernsheimer | M. Hou | D. Provan | V. Mcdonald | N. Cooper | T. González‐López
[1] G. Moulis,et al. Positivity rate of systematic bone marrow smear in patients over 60 years old with newly diagnosed immune thrombocytopenia. , 2020, Blood advances.
[2] M. Lapeyre-Mestre,et al. Significance of antinuclear antibodies in primary immune thrombocytopenia: results of the CARMEN registry. , 2020, Blood advances.
[3] E. Andrès,et al. Thrombocytopenia in the Course of COVID-19 Infection , 2020, European journal of case reports in internal medicine.
[4] M. Makris,et al. Practical guidance for the management of adults with immune thrombocytopenia during the COVID‐19 pandemic , 2020, British journal of haematology.
[5] Y. Tomiyama,et al. Risk factors for skin, mucosal, and organ bleeding in adults with primary ITP: a nationwide study in Japan. , 2020, Blood advances.
[6] L. Laura,et al. Use of Romiplostim during pregnancy as a rescue therapy in primary immune thrombocytopenia: Literature review and case description , 2020, Platelets.
[7] H. Al‐Samkari,et al. A modern reassessment of glycoprotein-specific direct platelet autoantibody testing in immune thrombocytopenia. , 2020, Blood advances.
[8] G. Salles,et al. Long‐term safety and efficacy of rituximab in 248 adults with immune thrombocytopenia: Results at 5 years from the French prospective registry ITP‐ritux , 2019, American journal of hematology.
[9] L. Vercellino,et al. Autologous111Indium‐oxinate‐labelled platelet sequestration study in patients with immune thrombocytopenia treated by thrombopoietin receptor‐agonists , 2019, British journal of haematology.
[10] J. Bussel,et al. Health‐related quality of life in children with chronic immune thrombocytopenia treated with eltrombopag in the PETIT study , 2019, British journal of haematology.
[11] J. Bussel,et al. Long‐term fostamatinib treatment of adults with immune thrombocytopenia during the phase 3 clinical trial program , 2019, American journal of hematology.
[12] B. Chong,et al. Romiplostim in adult patients with newly diagnosed or persistent immune thrombocytopenia (ITP) for up to 1 year and in those with chronic ITP for more than 1 year: a subgroup analysis of integrated data from completed romiplostim studies , 2019, British journal of haematology.
[13] J. Bussel,et al. Platelet transfusion practices in immune thrombocytopenia related hospitalizations , 2018, Transfusion.
[14] J. Annichino-Bizzacchi,et al. A retrospective analysis of 122 immune thrombocytopenia patients treated with dapsone: Efficacy, safety and factors associated with treatment response , 2018, Journal of thrombosis and haemostasis : JTH.
[15] J. Bussel,et al. Changes in health‐related quality of life with long‐term eltrombopag treatment in adults with persistent/chronic immune thrombocytopenia: Findings from the EXTEND study , 2018, American journal of hematology.
[16] H. Al‐Samkari,et al. Antiplatelet Antibody Testing in Immune Thrombocytopenia and Evans Syndrome: Longitudinal Serologic Evolution and Relation to Clinical Features , 2018, Blood.
[17] J. Bussel,et al. Patients with Immune Thrombocytopenia (ITP) Frequently Experience Severe Fatigue but Is It Under-Recognized By Physicians: Results from the ITP World Impact Survey (I-WISh) , 2018, Blood.
[18] S. Vesely,et al. Platelet sequestration and consumption in the placental intervillous space contribute to lower platelet counts during pregnancy , 2018, American journal of hematology.
[19] Q. Hill,et al. Immune thrombocytopenia: improving quality of life and patient outcomes , 2018, Patient related outcome measures.
[20] L. Ribeiro,et al. Severe immune thrombocytopenia in pregnancy treated with Eltrombopag - A case report. , 2018, Journal of gynecology obstetrics and human reproduction.
[21] H. Al‐Samkari,et al. Thrombopoietin level predicts response to treatment with eltrombopag and romiplostim in immune thrombocytopenia , 2018, American journal of hematology.
[22] L. F. Allen,et al. Avatrombopag, an oral thrombopoietin receptor agonist: results of two double‐blind, dose‐rising, placebo‐controlled Phase 1 studies , 2018, British journal of haematology.
[23] L. F. Allen,et al. Phase 3 randomised study of avatrombopag, a novel thrombopoietin receptor agonist for the treatment of chronic immune thrombocytopenia , 2018, British journal of haematology.
[24] C. Uiterwaal,et al. Intravenous immunoglobulin vs observation in childhood immune thrombocytopenia: a randomized controlled trial. , 2018, Blood.
[25] H. Al‐Samkari,et al. An alternative intermittent eltrombopag dosing protocol for the treatment of chronic immune thrombocytopenia , 2018, British journal of clinical pharmacology.
[26] M. Lapeyre-Mestre,et al. Risk factors for bleeding, including platelet count threshold, in newly diagnosed immune thrombocytopenia adults , 2018, Journal of thrombosis and haemostasis : JTH.
[27] S. Vesely,et al. Platelet Counts during Pregnancy , 2018, The New England journal of medicine.
[28] H. Al‐Samkari,et al. Relative potency of the thrombopoietin receptor agonists eltrombopag, avatrombopag and romiplostim in a patient with chronic immune thrombocytopenia , 2018, British journal of haematology.
[29] F. Brunetti,et al. Systematic detection of portal or splenic vein thrombosis after splenectomy for immune cytopenia , 2018, American journal of hematology.
[30] Y. Kagami,et al. A low birth weight infant with no malformations delivered by a primary immune thrombocytopenia patient treated with eltrombopag , 2018, International Journal of Hematology.
[31] Jiří Mayer,et al. Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: Results of two phase 3, randomized, placebo‐controlled trials , 2018, American journal of hematology.
[32] F. Rodeghiero. A critical appraisal of the evidence for the role of splenectomy in adults and children with ITP , 2018, British journal of haematology.
[33] Z. Alfirevic,et al. Severe primary autoimmune thrombocytopenia in pregnancy: a national cohort study , 2018, BJOG : an international journal of obstetrics and gynaecology.
[34] J. Gottenberg,et al. Efficacy and safety of rituximab for systemic lupus erythematosus‐associated immune cytopenias: A multicenter retrospective cohort study of 71 adults , 2018, American journal of hematology.
[35] Y. Iwashita,et al. Long-term outcomes of laparoscopic versus open splenectomy for immune thrombocytopenia , 2018, Surgery Today.
[36] M. Miyazaki,et al. Long-term efficacy of partial splenic embolization for the treatment of steroid-resistant chronic immune thrombocytopenia , 2018, Annals of Hematology.
[37] S. Vesely,et al. Predictors of remission in children with newly diagnosed immune thrombocytopenia: Data from the Intercontinental Cooperative ITP Study Group Registry II participants , 2018, Pediatric blood & cancer.
[38] H. Al‐Samkari,et al. Romiplostim for the management of perioperative thrombocytopenia , 2017, British journal of haematology.
[39] J. Bussel,et al. Safety and efficacy of long-term treatment of chronic/persistent ITP with eltrombopag: final results of the EXTEND study. , 2017, Blood.
[40] J. Bussel,et al. Treatment of Children with Persistent and Chronic Idiopathic Thrombocytopenic Purpura: 4 Infusions of Rituximab and Three 4‐Day Cycles of Dexamethasone , 2017, The Journal of pediatrics.
[41] J. Kelton,et al. Misdiagnosis of primary immune thrombocytopenia and frequency of bleeding: lessons from the McMaster ITP Registry. , 2017, Blood advances.
[42] M. Hernandez,et al. Thrombopoietin receptor agonist switch in adult primary immune thrombocytopenia patients: A retrospective collaborative survey involving 4 Spanish centres , 2017, European journal of haematology.
[43] Mohsen Saleh Elalfy,et al. A randomized multicenter study: safety and efficacy of mini‐pool intravenous immunoglobulin versus standard immunoglobulin in children aged 1‐18 years with immune thrombocytopenia , 2017, Transfusion.
[44] M. Hou,et al. A novel recombinant human thrombopoietin therapy for the management of immune thrombocytopenia in pregnancy. , 2017, Blood.
[45] L. Abenhaim,et al. Childhood immune thrombocytopenia: A nationwide cohort study on condition management and outcomes , 2017, Pediatric blood & cancer.
[46] Yanli Wang,et al. Thrombocytopenia in pregnancy with different diagnoses , 2017, Medicine.
[47] J. González-Porras,et al. Efficacy and safety of eltrombopag in persistent and newly diagnosed ITP in clinical practice , 2017, International Journal of Hematology.
[48] M. Lapeyre-Mestre,et al. Newly diagnosed immune thrombocytopenia adults: Clinical epidemiology, exposure to treatments, and evolution. Results of the CARMEN multicenter prospective cohort , 2017, American journal of hematology.
[49] Kevin L. Wethington,et al. Risk of Epidural Hematoma after Neuraxial Techniques in Thrombocytopenic Parturients: A Report from the Multicenter Perioperative Outcomes Group , 2017, Anesthesiology.
[50] D. Patel,et al. Sports participation recommendations for patients with bleeding disorders. , 2017, Translational pediatrics.
[51] A. Cybulska,et al. Measurements of immature platelets with haematology analysers are of limited value to separate immune thrombocytopenia from bone marrow failure , 2017, British journal of haematology.
[52] F. Laskou,et al. Thrombopoetin receptor agonist therapy in thrombocytopenia: ITP and beyond , 2017, British journal of haematology.
[53] M. Steurer,et al. Safety and efficacy of romiplostim in splenectomized and nonsplenectomized patients with primary immune thrombocytopenia , 2017, Haematologica.
[54] R. Fanin,et al. Rituximab in immune thrombocytopenia: gender, age, and response as predictors of long‐term response , 2017, European journal of haematology.
[55] A. Matucci,et al. Rapid infusions of human normal immunoglobulin 50 g/l are safe and well tolerated in immunodeficiencies and immune thrombocytopenia , 2017, International immunopharmacology.
[56] Huiyuan Li,et al. Long‐term results of splenectomy in adult chronic immune thrombocytopenia , 2017, European journal of haematology.
[57] M. Steurer,et al. A large observational study of patients with primary immune thrombocytopenia receiving romiplostim in European clinical practice , 2017, European journal of haematology.
[58] M. Brouwers,et al. Reporting Items for Updated Clinical Guidelines: Checklist for the Reporting of Updated Guidelines (CheckUp) , 2017, PLoS medicine.
[59] Jie Jin,et al. Multicentre, randomised phase III study of the efficacy and safety of eltrombopag in Chinese patients with chronic immune thrombocytopenia , 2017, British journal of haematology.
[60] R. Brynes,et al. A 2-Year, Longitudinal, Prospective Study of the Effects of Eltrombopag on Bone Marrow in Patients with Chronic Immune Thrombocytopenia , 2016, Acta Haematologica.
[61] V. Ramanan,et al. Safety and efficacy of a 10% intravenous immunoglobulin preparation in patients with immune thrombocytopenic purpura: results of two international, multicenter studies. , 2016, Immunotherapy.
[62] F. Xue,et al. The Effect of Danazol in Primary Immune Thrombocytopenia , 2016, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.
[63] F. Pruvot,et al. Reemergence of Splenectomy for ITP Second-line Treatment? , 2016, Annals of surgery.
[64] A. Mondino,et al. Mycophenolate mofetil for the treatment of children with immune thrombocytopenia and Evans syndrome. A retrospective data review from the Italian association of paediatric haematology/oncology , 2016, British journal of haematology.
[65] F. Roudot-thoraval,et al. Long-term complications of splenectomy in adult immune thrombocytopenia , 2016, Medicine.
[66] W. Frenzel,et al. Tolerability and safety of Octagam® (IVIG): a post-authorization safety analysis of four non-interventional phase IV trials , 2016, International journal of clinical pharmacology and therapeutics.
[67] Matthew C. Miller,et al. High-dose dexamethasone compared with prednisone for previously untreated primary immune thrombocytopenia: a systematic review and meta-analysis. , 2016, The Lancet. Haematology.
[68] J. Payen,et al. Reduced mortality by meeting guideline criteria before using recombinant activated factor VII in severe trauma patients with massive bleeding. , 2016, British journal of anaesthesia.
[69] F. Mandelli,et al. Health‐related quality of life and burden of fatigue in patients with primary immune thrombocytopenia by phase of disease , 2016, American journal of hematology.
[70] A. Cuker,et al. How I treat refractory immune thrombocytopenia. , 2016, Blood.
[71] P. Shah,et al. Corticosteroids compared with intravenous immunoglobulin for the treatment of immune thrombocytopenia in pregnancy. , 2016, Blood.
[72] J. Zehnder,et al. Gender and duration of disease differentiate responses to rituximab–dexamethasone therapy in adults with immune thrombocytopenia , 2016, American journal of hematology.
[73] J. González-Porras,et al. Eltrombopag safety and efficacy for primary chronic immune thrombocytopenia in clinical practice , 2016, European journal of haematology.
[74] L. Abenhaim,et al. Immune thrombocytopenia in adults: a prospective cohort study of clinical features and predictors of outcome , 2016, Haematologica.
[75] D. Kuter,et al. Remissions after long-term use of romiplostim for immune thrombocytopenia , 2016, Haematologica.
[76] P. Forbes,et al. Thrombopoietin Receptor Agonist Use in Children: Data From the Pediatric ITP Consortium of North America ICON2 Study , 2016, Pediatric blood & cancer.
[77] A. Raj,et al. Romiplostim in children with immune thrombocytopenia: a phase 3, randomised, double-blind, placebo-controlled study , 2016, The Lancet.
[78] Aswath Kumar,et al. A case of refractory immune thrombocytopenia in pregnancy managed with elthrombopag , 2016, Asian journal of transfusion science.
[79] M. Michel,et al. How we manage immune thrombocytopenia in the elderly , 2016, British journal of haematology.
[80] U. Dührsen,et al. A Randomized Trial of Daily Prednisone versus Pulsed Dexamethasone in Treatment-Naïve Adult Patients with Immune Thrombocytopenia: EIS 2002 Study , 2016, Acta Haematologica.
[81] R. Fanin,et al. Thrombopoietin receptor agonists for preparing adult patients with immune thrombocytopenia to splenectomy: results of a retrospective, observational GIMEMA study , 2016, American journal of hematology.
[82] B. Chong,et al. Changes in bone marrow morphology in adults receiving romiplostim for the treatment of thrombocytopenia associated with primary immune thrombocytopenia , 2016, Annals of Hematology.
[83] V. Blanchette,et al. A Phase 3, Randomized, Double‐Blind, Placebo‐Controlled Study to Determine the Effect of Romiplostim on Health‐Related Quality of Life in Children with Primary Immune Thrombocytopenia and Associated Burden in Their Parents , 2016, Pediatric blood & cancer.
[84] P. Bierling,et al. Vincristine efficacy and safety in treating immune thrombocytopenia: a retrospective study of 35 patients , 2016, European journal of haematology.
[85] Gunawardena Dammika,et al. Identifying the characteristics, natural behavioral pattern, and response to therapy in ITP in a multi-center population in Sri Lanka , 2016, Hematology.
[86] M. Lee,et al. Clinical efficacy and tolerability of vincristine in splenectomized patients with refractory or relapsed immune thrombocytopenia: a retrospective single-center study , 2016, International Journal of Hematology.
[87] M. Hou,et al. Thrombopoietin: a potential diagnostic indicator of immune thrombocytopenia in pregnancy , 2016, Oncotarget.
[88] M. Hou,et al. High-dose dexamethasone vs prednisone for treatment of adult immune thrombocytopenia: a prospective multicenter randomized trial. , 2016, Blood.
[89] Guk Jin Lee,et al. Clinical Outcome and Predictive Factors in the Response to Splenectomy in Elderly Patients with Primary Immune Thrombocytopenia: A Multicenter Retrospective Study , 2016, Acta Haematologica.
[90] J. Viallard,et al. Remission and platelet responses with romiplostim in primary immune thrombocytopenia: final results from a phase 2 study , 2016, British journal of haematology.
[91] E. Neufeld,et al. Sports Participation in Children and Adolescents with Immune Thrombocytopenia (ITP) , 2015, Pediatric blood & cancer.
[92] M. Scully,et al. Mycophenolate mofetil therapy for severe immune thrombocytopenia , 2015, British journal of haematology.
[93] J. Bussel,et al. Eltrombopag for children with chronic immune thrombocytopenia (PETIT2): a randomised, multicentre, placebo-controlled trial , 2015, The Lancet.
[94] Y. Miyakawa,et al. Efficacy and safety of rituximab in Japanese patients with relapsed chronic immune thrombocytopenia refractory to conventional therapy , 2015, International Journal of Hematology.
[95] D. Kuter,et al. Romiplostim in the management of the thrombocytopenic surgical patient , 2015, Transfusion.
[96] Y. Tomiyama,et al. Efficacy and safety of the thrombopoietin receptor agonist romiplostim in patients aged ≥65 years with immune thrombocytopenia , 2015, Annals of Hematology.
[97] J. Bussel,et al. Eltrombopag for the treatment of children with persistent and chronic immune thrombocytopenia (PETIT): a randomised, multicentre, placebo-controlled study. , 2015, The Lancet. Haematology.
[98] J. Wasser,et al. Integrated analysis of long-term safety in patients with chronic immune thrombocytopaenia (ITP) treated with the thrombopoietin (TPO) receptor agonist romiplostim , 2015, International Journal of Hematology.
[99] A. Newland,et al. Fatigue in immune thrombocytopenia , 2015, British journal of haematology.
[100] R. Brynes,et al. Evaluation of bone marrow reticulin in patients with chronic immune thrombocytopenia treated with eltrombopag: Data from the EXTEND study , 2015, American journal of hematology.
[101] M. Steurer,et al. Romiplostim Treatment in Adults with Immune Thrombocytopenia of Varying Duration and Severity , 2015, Acta Haematologica.
[102] M. Calaminici,et al. United Kingdom immune thrombocytopenia registry: retrospective evaluation of bone marrow fibrosis in adult patients with primary immune thrombocytopenia and correlation with clinical findings , 2015, British journal of haematology.
[103] A. Waage,et al. Rituximab as second-line treatment for adult immune thrombocytopenia (the RITP trial): a multicentre, randomised, double-blind, placebo-controlled trial , 2015, The Lancet.
[104] J. González-Porras,et al. Use of eltrombopag after romiplostim in primary immune thrombocytopenia , 2015, British journal of haematology.
[105] J. Kelton,et al. Rituximab plus standard of care for treatment of primary immune thrombocytopenia: a systematic review and meta-analysis. , 2015, The Lancet. Haematology.
[106] D. Kuter,et al. Treatment patterns and clinical outcomes in patients with chronic immune thrombocytopenia (ITP) switched to eltrombopag or romiplostim , 2015, International Journal of Hematology.
[107] F. Hirahara,et al. Clinical features of gestational thrombocytopenia difficult to differentiate from immune thrombocytopenia diagnosed during pregnancy , 2015, The journal of obstetrics and gynaecology research.
[108] P. Galan,et al. Successful discontinuation of eltrombopag after complete remission in patients with primary immune thrombocytopenia , 2014, American journal of hematology.
[109] G. Salles,et al. Safety and efficacy of rituximab in adult immune thrombocytopenia: results from a prospective registry including 248 patients. , 2014, Blood.
[110] M. Romano,et al. The choice of second‐line therapy in steroid‐resistant immune thrombocytopenia: Role of platelet kinetics in a single‐centre long‐term study , 2014, American journal of hematology.
[111] J. Bussel,et al. Long-Term Use of the Thrombopoietin-Mimetic Romiplostim in Children With Severe Chronic Immune Thrombocytopenia (ITP) , 2014, Pediatric blood & cancer.
[112] M. Gandhi,et al. A multi‐centre, single‐arm, open‐label study evaluating the safety and efficacy of fixed dose rituximab in patients with refractory, relapsed or chronic idiopathic thrombocytopenic purpura (R‐ITP1000 study) , 2014, British journal of haematology.
[113] L. Haverman,et al. Health-related quality of life in children with newly diagnosed immune thrombocytopenia , 2014, Haematologica.
[114] P. Bierling,et al. Effect of pregnancy on the course of immune thrombocytopenia: a retrospective study of 118 pregnancies in 82 women , 2014, British journal of haematology.
[115] K. Lee,et al. Natural course of childhood chronic immune thrombocytopenia using the revised terminology and definitions of the international working group: a single center experience , 2014, Blood research.
[116] T. Pekmezović,et al. Health-related quality of life in adult patients with chronic immune thrombocytopenia in Serbia , 2014, Platelets.
[117] L. Marcellin,et al. Rescue Therapy With Romiplostim for Refractory Primary Immune Thrombocytopenia During Pregnancy , 2014, Obstetrics and gynecology.
[118] G. Gaidano,et al. Thrombotic risk in patients with primary immune thrombocytopenia is only mildly increased and explained by personal and treatment‐related risk factors , 2014, Journal of thrombosis and haemostasis : JTH.
[119] R. Elstrom,et al. Rituximab and three dexamethasone cycles provide responses similar to splenectomy in women and those with immune thrombocytopenia of less than two years duration , 2014, Haematologica.
[120] J. Bussel,et al. A randomized trial of avatrombopag, an investigational thrombopoietin-receptor agonist, in persistent and chronic immune thrombocytopenia. , 2014, Blood.
[121] C. Dash,et al. Safety and Efficacy of Gammaplex® in Idiopathic Thrombocytopenic Purpura (ClinicalTrials.gov - NCT00504075) , 2014, PloS one.
[122] Yikun Qu,et al. Long-term outcomes of laparoscopic splenectomy versus open splenectomy for idiopathic thrombocytopenic purpura. , 2014, International surgery.
[123] J. Liu,et al. Association of autoantibody specificity and response to intravenous immunoglobulin G therapy in immune thrombocytopenia: a multicenter cohort study , 2014, Journal of thrombosis and haemostasis : JTH.
[124] H. Nakasone,et al. Prednisone versus high-dose dexamethasone for untreated primary immune thrombocytopenia. A retrospective study of the Japan Hematology & Oncology Clinical Study Group , 2014, Journal of Thrombosis and Thrombolysis.
[125] F. Roudot-thoraval,et al. Hydroxychloroquine is a good second‐line treatment for adults with immune thrombocytopenia and positive antinuclear antibodies , 2014, American journal of hematology.
[126] R. Hoover,et al. Long-term risks after splenectomy among 8,149 cancer-free American veterans: a cohort study with up to 27 years follow-up , 2014, Haematologica.
[127] M. Lapeyre-Mestre,et al. Rituximab versus splenectomy in persistent or chronic adult primary immune thrombocytopenia: an adjusted comparison of mortality and morbidity , 2014, American journal of hematology.
[128] D. Kuter,et al. Thrombopoietin levels in patients with disorders of platelet production: Diagnostic potential and utility in predicting response to TPO Receptor agonists , 2013, American journal of hematology.
[129] F. Roudot-thoraval,et al. Efficacy and safety of rituximab given at 1,000 mg on days 1 and 15 compared to the standard regimen to treat adult immune thrombocytopenia , 2013, American journal of hematology.
[130] J. Kelton,et al. The effect of rituximab on vaccine responses in patients with immune thrombocytopenia. , 2013, Blood.
[131] V. Blanchette,et al. Quality of life in immune thrombocytopenia following treatment , 2013, Archives of Disease in Childhood.
[132] A. James,et al. Use of a Thrombopoietin Mimetic for Chronic Immune Thrombocytopenic Purpura in Pregnancy , 2013, Obstetrics and gynecology.
[133] Y. Miyakawa,et al. Oral eltrombopag for up to three years is safe and well-tolerated in Japanese patients with previously treated chronic immune thrombocytopenia: an open-label, extension study , 2013, International Journal of Hematology.
[134] M. Trivella,et al. Antifibrinolytics (lysine analogues) for the prevention of bleeding in patients with haematological disorders. , 2013, The Cochrane database of systematic reviews.
[135] Y. Dallar,et al. A comparison of intravenous immunoglobulin (2 g/kg totally) and single doses of anti-D immunoglobulin at 50 &mgr;g/kg, 75 &mgr;g/kg in newly diagnosed children with idiopathic thrombocytopenic purpura: Ankara hospital experience , 2013, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.
[136] M. Baccarani,et al. Splenectomy as a curative treatment for immune thrombocytopenia: a retrospective analysis of 233 patients with a minimum follow up of 10 years , 2013, Haematologica.
[137] Ki-Jo Kim,et al. Thrombotic risk in patients with immune thrombocytopenia and its association with antiphospholipid antibodies , 2013, British journal of haematology.
[138] G. Ruiz-Argüelles,et al. High response rate to low‐dose rituximab plus high‐dose dexamethasone as frontline therapy in adult patients with primary immune thrombocytopenia , 2013, European journal of haematology.
[139] F. Roudot-thoraval,et al. A retrospective pilot evaluation of switching thrombopoietic receptor-agonists in immune thrombocytopenia , 2013, Haematologica.
[140] J. Bussel,et al. Long‐term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacy , 2013, British journal of haematology.
[141] J. Klima,et al. Patterns of Inpatient Care for Newly Diagnosed Immune Thrombocytopenia in US Children’s Hospitals , 2013, Pediatrics.
[142] P. Noris,et al. Platelet size for distinguishing between inherited thrombocytopenias and immune thrombocytopenia: a multicentric, real life study , 2013, British journal of haematology.
[143] J. Bussel,et al. Standardization of bleeding assessment in immune thrombocytopenia: report from the International Working Group. , 2013, Blood.
[144] M. Tarantino,et al. Efficacy of eltrombopag in management of bleeding symptoms associated with chronic immune thrombocytopenia , 2013, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.
[145] M. Moritz,et al. Ciclosporin Use During Pregnancy , 2013, Drug Safety.
[146] L. Kjeldsen,et al. Rituximab and dexamethasone vs dexamethasone monotherapy in newly diagnosed patients with primary immune thrombocytopenia. , 2013, Blood.
[147] R. Vecchio,et al. Long-term results after splenectomy in adult idiopathic thrombocytopenic purpura: comparison between open and laparoscopic procedures. , 2013, Journal of laparoendoscopic & advanced surgical techniques. Part A.
[148] J. Bussel,et al. Repeated short‐term use of eltrombopag in patients with chronic immune thrombocytopenia (ITP) , 2013, British journal of haematology.
[149] S. Uslu,et al. Comparison of anti-D immunoglobulin, methylprednisolone, or intravenous immunoglobulin therapy in newly diagnosed pediatric immune thrombocytopenic purpura , 2013, Journal of Thrombosis and Thrombolysis.
[150] L. Abenhaim,et al. A case-control study to assess the risk of immune thrombocytopenia associated with vaccines. , 2012, Blood.
[151] Udipta Ray,et al. Laparoscopic versus open splenectomy in the treatment of idiopathic thrombocytopenic purpura: an Indian experience. , 2012, Journal of the Indian Medical Association.
[152] S. Alkindi,et al. Successful treatment of severe thrombocytopenia with romiplostim in a pregnant patient with systemic lupus erythematosus , 2012, Lupus.
[153] M. Šimkovič,et al. Efficacy of rituximab in primary immune thrombocytopenia: an analysis of adult pretreated patients from everyday hematological practice , 2012, International Journal of Hematology.
[154] F. Sedel,et al. The French Gaucher’s disease registry: clinical characteristics, complications and treatment of 562 patients , 2012, Orphanet Journal of Rare Diseases.
[155] R. Fanin,et al. Long‐term follow‐up analysis after rituximab salvage therapy in adult patients with immune thrombocytopenia , 2012, American journal of hematology.
[156] N. Chang,et al. A multicenter randomized controlled trial of recombinant human thrombopoietin treatment in patients with primary immune thrombocytopenia , 2012, International Journal of Hematology.
[157] E. Neufeld,et al. Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia. , 2012, Blood.
[158] J. Viallard,et al. Evaluation of bleeding-related episodes in patients with immune thrombocytopenia (ITP) receiving romiplostim or medical standard of care , 2012, International Journal of Hematology.
[159] A. Giagounidis,et al. Health‐related quality of life in nonsplenectomized immune thrombocytopenia patients receiving romiplostim or medical standard of care , 2012, American journal of hematology.
[160] Y. Miyakawa,et al. A lower starting dose of eltrombopag is efficacious in Japanese patients with previously treated chronic immune thrombocytopenia , 2012, Journal of thrombosis and haemostasis : JTH.
[161] J. Bussel,et al. RhIG for the treatment of immune thrombocytopenia: consensus and controversy (CME) , 2012, Transfusion.
[162] K. Kirito,et al. An open-label extension study evaluating the safety and efficacy of romiplostim for up to 3.5 years in thrombocytopenic Japanese patients with immune thrombocytopenic purpura (ITP) , 2012, International Journal of Hematology.
[163] B. Myers,et al. Eltrombopag named patient programme for patients with chronic immune thrombocytopenia , 2012, British journal of haematology.
[164] J. Bussel,et al. Pilot study of the effect of romiplostim on child health‐related quality of life (HRQoL) and parental burden in immune thrombocytopenia (ITP) , 2012, Pediatric blood & cancer.
[165] R. Fanin,et al. Dapsone salvage therapy for adult patients with immune thrombocytopenia relapsed or refractory to steroid and rituximab , 2012, American journal of hematology.
[166] D. Cook,et al. A pilot randomized trial of adjuvant rituximab or placebo for nonsplenectomized patients with immune thrombocytopenia. , 2012, Blood.
[167] R. Davis,et al. The Risk of Immune Thrombocytopenic Purpura After Vaccination in Children and Adolescents , 2012, Pediatrics.
[168] E. Neufeld,et al. Response to steroids predicts response to rituximab in pediatric chronic immune thrombocytopenia , 2012, Pediatric blood & cancer.
[169] G. Koren,et al. Safety of azathioprine use during pregnancy. , 2011, Canadian family physician Medecin de famille canadien.
[170] H. Tamary,et al. Newly diagnosed immune thrombocytopenia in children and adults: a comparative prospective observational registry of the Intercontinental Cooperative Immune Thrombocytopenia Study Group , 2011, Haematologica.
[171] R. White,et al. Splenectomy and the incidence of venous thromboembolism and sepsis in patients with immune thrombocytopenia. , 2011, Blood.
[172] P. Bolton-Maggs,et al. Changing trends in the UK management of childhood ITP , 2011, Archives of Disease in Childhood.
[173] J. Rossi,et al. Romiplostim safety and efficacy for immune thrombocytopenia in clinical practice: 2-year results of 72 adults in a romiplostim compassionate-use program. , 2011, Blood.
[174] Yichao Wang,et al. Laparoscopic splenectomy for patients with immune thrombocytopenia and very low platelet count: is platelet transfusion necessary? , 2011, The Journal of surgical research.
[175] J. Landman-Parker,et al. Vinblastine in the treatment of children and adolescents with refractory immune thrombocytopenia , 2011, American journal of hematology.
[176] Yow-Ming C Wang,et al. A randomized, double-blind study of romiplostim to determine its safety and efficacy in children with immune thrombocytopenia. , 2011, Blood.
[177] K. Kirito,et al. Romiplostim for the treatment of chronic immune thrombocytopenia in adult Japanese patients: a double-blind, randomized Phase III clinical trial , 2011, International journal of hematology.
[178] A. Wolanskyj,et al. Accessory splenectomy for refractory immune thrombocytopenic purpura , 2011, American journal of hematology.
[179] G. Bozkaya,et al. Comparison of conventional dose steroid treatment and high dose steroid treatment as run-in regime for splenectomy in immune thrombocytopenic purpura (ITP). , 2011, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.
[180] M. Economou,et al. Standard-dose Intravenous Anti-D Immunoglobulin Versus Intravenous Immunoglobulin in the Treatment of Newly Diagnosed Childhood Primary Immune Thrombocytopenia , 2011, Journal of pediatric hematology/oncology.
[181] S. Vesely,et al. Fatigue in adult patients with primary immune thrombocytopenia , 2011, European journal of haematology.
[182] M. Crowther,et al. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. , 2011, Blood.
[183] Mohsen Saleh Elalfy,et al. Romiplostim in children with chronic refractory ITP: randomized placebo controlled study , 2011, Annals of Hematology.
[184] M. Čolović,et al. Mycophenolate mophetil therapy for chronic immune thrombocytopenic purpura resistant to steroids, immunosuppressants, and/or splenectomy in adults , 2011, Platelets.
[185] E. Chakravarty,et al. Pregnancy outcomes after maternal exposure to rituximab. , 2011, Blood.
[186] F. Branciforte,et al. Effect of eradication of Helicobacter pylori in children with chronic immune thrombocytopenia: A prospective, controlled, multicenter study , 2011, Pediatric blood & cancer.
[187] J. Bussel,et al. Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study , 2011, The Lancet.
[188] D. Cines,et al. Evidence-based mini-review: Is indium-labeled autologous platelet scanning predictive of response to splenectomy in patients with chronic immune thrombocytopenia? , 2010, Hematology. American Society of Hematology. Education Program.
[189] Manuel Solano-Genesta,et al. Low-dose rituximab and alemtuzumab combination therapy for patients with steroid-refractory autoimmune cytopenias. , 2010, Blood.
[190] A. Newland,et al. Autologous 111In‐labelled platelet sequestration studies in patients with primary immune thrombocytopenia (ITP) prior to splenectomy: a report from the United Kingdom ITP Registry , 2010, British journal of haematology.
[191] B. Chong,et al. Romiplostim or standard of care in patients with immune thrombocytopenia. , 2010, The New England journal of medicine.
[192] T. Robak,et al. Efficacy and safety of a new intravenous immunoglobulin 10% formulation (octagam® 10%) in patients with immune thrombocytopenia , 2010, Hematology.
[193] R. Fanin,et al. Low‐dose rituximab in adult patients with primary immune thrombocytopenia , 2010, European journal of haematology.
[194] J. Logie,et al. Thromboembolic events among adult patients with primary immune thrombocytopenia in the United Kingdom General Practice Research Database , 2010, Haematologica.
[195] J. George,et al. Evaluation of bleeding and thrombotic events during long‐term use of romiplostim in patients with chronic immune thrombocytopenia (ITP) , 2010, Journal of thrombosis and haemostasis : JTH.
[196] R. Fanin,et al. Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia. , 2010, Blood.
[197] J. Bussel,et al. Comparison of intravenous immune globulin and high dose anti‐D immune globulin as initial therapy for childhood immune thrombocytopenic purpura , 2010, British journal of haematology.
[198] S. Mohamed,et al. Systemic thromboembolic complications after laparoscopic splenectomy for idiopathic thrombocytopenic purpura in comparison to open surgery in the absence of anticoagulant prophylaxis. , 2010, Hematology/oncology and stem cell therapy.
[199] Drew Provan,et al. International consensus report on the investigation and management of primary immune thrombocytopenia. , 2010, Blood.
[200] J. Kelton,et al. Combination immunosuppressant therapy for patients with chronic refractory immune thrombocytopenic purpura. , 2010, Blood.
[201] M. Kubota,et al. Characterization of chronic idiopathic thrombocytopenic purpura in Japanese children: a retrospective multi-center study , 2010, International journal of hematology.
[202] R. Saxena,et al. High dose dexamethasone therapy shows better responses in acute immune thrombocytopenia than in chronic immune thrombocytopenia , 2010, Platelets.
[203] H. Hasle,et al. Subcutaneous anti‐D treatment of idiopathic thrombocytopenic purpura in children , 2009, Pediatric blood & cancer.
[204] N. Elbarbary,et al. Intracranial Hemorrhage in Acute and Chronic Childhood Immune Thrombocytopenic Purpura over a Ten-Year Period: An Egyptian Multicenter Study , 2009, Acta Haematologica.
[205] S. Vesely,et al. Bleeding manifestations and management of children with persistent and chronic immune thrombocytopenia: data from the Intercontinental Cooperative ITP Study Group (ICIS). , 2009, Blood.
[206] Yong-chun Su,et al. A retrospective analysis of therapeutic responses to two distinct corticosteroids in 259 children with acute primary idiopathic thrombocytopenic purpura , 2009, Hematology.
[207] J. Leonard,et al. Repeated courses of rituximab in chronic ITP: Three different regimens , 2009, American journal of hematology.
[208] S. Vesely,et al. Corticosteroid side‐effects and risk for bleeding in immune thrombocytopenic purpura: patient and hematologist perspectives , 2009, European journal of haematology.
[209] T. Robak,et al. Efficacy and safety of Privigen®, a novel liquid intravenous immunoglobulin formulation, in adolescent and adult patients with chronic immune thrombocytopenic purpura , 2009, Hematology.
[210] E. Katodritou,et al. Quantifying the reduction in immunoglobulin use over time in patients with chronic immune thrombocytopenic purpura receiving romiplostim (AMG 531) , 2009, American journal of hematology.
[211] A. Chuansumrit,et al. Absence of platelet recovery following Helicobacter pylori eradication in childhood chronic idiopathic thrombocytopenic purpura: A multi‐center randomized controlled trial , 2009, Pediatric blood & cancer.
[212] R. Tamminga,et al. Possible lower rate of chronic ITP after IVIG for acute childhood ITP an analysis from registry I of the Intercontinental Cooperative ITP Study Group (ICIS) , 2009, British journal of haematology.
[213] A. Delannoy,et al. Rituximab in auto‐immune haemolytic anaemia and immune thrombocytopenic purpura: a Belgian retrospective multicentric study , 2009, Journal of internal medicine.
[214] W. Praituan,et al. Faster platelet recovery by high‐dose dexamethasone compared with standard‐dose prednisolone in adult immune thrombocytopenia: a prospective randomized trial , 2009, Journal of thrombosis and haemostasis : JTH.
[215] T. Nakahata,et al. AKR‐501 (YM477) a novel orally‐active thrombopoietin receptor agonist , 2009, European journal of haematology.
[216] J. Thachil,et al. Guidelines for the diagnosis and management of disseminated intravascular coagulation , 2009, British journal of haematology.
[217] O. Ayyıldız,et al. The efficacy of rituximab in patients with splenectomized refractory chronic idiopathic thrombocythopenic purpura , 2009, Journal of Thrombosis and Thrombolysis.
[218] J. George,et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. , 2009, Blood.
[219] J. Bussel,et al. Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP. , 2009, Blood.
[220] J. Bussel,et al. Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial , 2009, The Lancet.
[221] J. Segal,et al. Effects of eradication of Helicobacter pylori infection in patients with immune thrombocytopenic purpura: a systematic review. , 2009, Blood.
[222] A. Wu,et al. Evaluating clinically meaningful change on the ITP-PAQ: preliminary estimates of minimal important differences , 2009 .
[223] M. Loh,et al. One year follow‐up of children and adolescents with chronic immune thrombocytopenic purpura (ITP) treated with rituximab , 2009, Pediatric blood & cancer.
[224] J. George,et al. Improved quality of life for romiplostim‐treated patients with chronic immune thrombocytopenic purpura: results from two randomized, placebo‐controlled trials , 2009, British journal of haematology.
[225] R. Calabrese,et al. Long‐term follow‐up analysis after rituximab therapy in children with refractory symptomatic ITP: identification of factors predictive of a sustained response , 2009, British journal of haematology.
[226] R. Saxena,et al. Efficacy and safety of anti-D for treatment of adults with immune thrombocytopenia , 2009, Platelets.
[227] J. Sweeney,et al. Laparoscopic Accessory Splenectomy for Recurrent Idiopathic Thrombocytopenic Purpura , 2008, JSLS : Journal of the Society of Laparoendoscopic Surgeons.
[228] Ken‐ichi Suzuki,et al. AKR-501 (YM477) in combination with thrombopoietin enhances human megakaryocytopoiesis. , 2008, Experimental hematology.
[229] P. Bierling,et al. Antiphospholipid antibodies in adults with immune thrombocytopenic purpura , 2008, British journal of haematology.
[230] J. George,et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial , 2008, The Lancet.
[231] G. Rodgers,et al. Treatment of immune‐mediated thrombocytopenia purpura with concurrent intravenous immunoglobulin and platelet transfusion: A retrospective review of 40 patients , 2008, American journal of hematology.
[232] J. Bussel,et al. Diagnosis, pathophysiology and management of children with refractory immune thrombocytopenic purpura , 2008, Current opinion in pediatrics.
[233] C. Obispo,et al. The levonorgestrel intrauterine system (Mirena®) for treatment of idiopathic menorrhagia. Assessment of quality of life and satisfaction , 2008, The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception.
[234] R. Barker,et al. A high rate of CLL phenotype lymphocytes in autoimmune hemolytic anemia and immune thrombocytopenic purpura , 2008, Haematologica.
[235] A. Venditti,et al. Idiopathic thrombocytopenic purpura: Current concepts in pathophysiology and management , 2007, Thrombosis and Haemostasis.
[236] R. Cohn,et al. Isolated thrombocytopenia in children: Thinking beyond idiopathic thrombocytopenic purpura and Leukaemia , 2007, Journal of paediatrics and child health.
[237] J. Bussel,et al. Multiagent induction and maintenance therapy for patients with refractory immune thrombocytopenic purpura (ITP). , 2007, Blood.
[238] H. Liebman. Other immune thrombocytopenias. , 2007, Seminars in hematology.
[239] R. Stasi,et al. Secondary immune thrombocytopenic purpura , 2007, Current opinion in hematology.
[240] E. Neufeld,et al. Validity, reliability, and responsiveness of a new measure of health-related quality of life in children with immune thrombocytopenic purpura: the Kids' ITP Tools. , 2007, The Journal of pediatrics.
[241] O. Ayyıldız,et al. Prevalence and clinical significance of elevated antinuclear antibody test in children and adult patients with idiopathic thrombocytopenic purpura , 2007, Journal of Thrombosis and Thrombolysis.
[242] R. Go,et al. The association between platelet autoantibody specificity and response to intravenous immunoglobulin G in the treatment of patients with immune thrombocytopenia. , 2006, Haematologica.
[243] A. Sikorska,et al. The use of vinca alkaloids in adult patients with refractory chronic idiopathic thrombocytopenia. , 2004, Clinical and laboratory haematology.
[244] J. Bussel,et al. Prospective screening of 205 patients with ITP, including diagnosis, serological markers, and the relationship between platelet counts, endogenous thrombopoietin, and circulating antithrombopoietin antibodies , 2004, American journal of hematology.
[245] J. Bussel,et al. Intravenous anti‐D as a treatment for immune thrombocytopenic purpura (ITP) during pregnancy , 2003, British journal of haematology.
[246] J. Kelton,et al. The IgG subclasses of platelet‐associated autoantibodies directed against platelet glycoproteins IIb/IIIa in patients with idiopathic thrombocytopenic purpura , 2003, British journal of haematology.
[247] B. Bader-Meunier,et al. Misdiagnosis of Chronic Thrombocytopenia in Childhood , 2003, Journal of pediatric hematology/oncology.
[248] Guidelines for the use of platelet transfusions , 2003, British journal of haematology.
[249] Dr Andre Braester. Pseudothrombocytopenia as a pitfall in the treatment of essential thrombocythemia , 2003, European journal of haematology.
[250] P. Tani,et al. Prospective evaluation of the immunobead assay for the diagnosis of adult chronic immune thrombocytopenic purpura (ITP) , 2003, Journal of thrombosis and haemostasis : JTH.
[251] W. Ouwehand,et al. Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy , 2003, British journal of haematology.
[252] Miha Furlan,et al. Von Willebrand factor-cleaving protease (ADAMTS13) in thrombocytopenic disorders: a severely deficient activity is specific for thrombotic thrombocytopenic purpura. , 2002, Blood.
[253] R. Harpold,et al. The Role of the Bone Marrow Examination in the Diagnosis of Immune Thrombocytopenic Purpura: Case Series and Literature Review , 2002, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.
[254] G. Naglie,et al. Initial Bone Marrow Aspiration in Childhood Idiopathic Thrombocytopenia: Decision Analysis , 2001, Journal of pediatric hematology/oncology.
[255] E. Gordon-Smith,et al. CAMPATH-1H in the treatment of autoimmune cytopenias. , 2001, Cytotherapy.
[256] R. Westendorp,et al. Morbidity and mortality in adults with idiopathic thrombocytopenic purpura. , 2001, Blood.
[257] C P Farrington,et al. Idiopathic thrombocytopenic purpura and MMR vaccine , 2001, Archives of disease in childhood.
[258] C. Chan,et al. The management of isolated thrombocytopenia in Chinese adults: does bone marrow examination have a role at presentation? , 2000, Clinical and laboratory haematology.
[259] B. Djulbegovic,et al. The bleeding risk and natural history of idiopathic thrombocytopenic purpura in patients with persistent low platelet counts. , 2000, Archives of internal medicine.
[260] M. Bayık,et al. Efficacy of high‐dose methylprednisolone as a first‐line therapy in adult patients with idiopathic thrombocytopenic purpura , 1998, British journal of haematology.
[261] Meltzer Rc,et al. Laparoscopic accessory splenectomy for recurrent idiopathic thrombocytopenic purpura. , 1997 .
[262] T. Kelly,et al. Maternal characteristics and risk of severe neonatal thrombocytopenia and intracranial hemorrhage in pregnancies complicated by autoimmune thrombocytopenia. , 1997, American journal of obstetrics and gynecology.
[263] J. George,et al. Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. , 1996, Blood.
[264] B. Chong,et al. Prospective evaluation of the clinical usefulness of an antigen-specific assay (MAIPA) in idiopathic thrombocytopenic purpura and other immune thrombocytopenias. , 1996, Blood.
[265] T. Barbui,et al. Prevalence and clinical significance of elevated antiphospholipid antibodies in patients with idiopathic thrombocytopenic purpura. , 1994, Blood.
[266] E. Wattel,et al. A randomized trial comparing vinblastine in slow infusion and by bolus i.v. injection in idiopathic thrombocytopenic purpura: a report on 42 patients , 1994, British journal of haematology.
[267] A. Manoharan. Targeted‐immunosuppression with vincristine infusion in the treatment of immune thrombocytopenia , 1991, Australian and New Zealand journal of medicine.
[268] P. Fenaux,et al. Slow infusions of vinblastine in the treatment of adult idiopathic thrombocytopenic purpura: A report on 43 cases , 1990, Blut.
[269] J. Stratton,et al. Mechanisms of response to treatment in autoimmune thrombocytopenic purpura. , 1989, The New England journal of medicine.
[270] A. von dem Borne,et al. High dose intravenous methylprednisolone or high dose intravenous gammaglobulin for autoimmune thrombocytopenia , 1988, British medical journal.
[271] J. M. Carr,et al. Efficacy of platelet transfusions in immune thrombocytopenia. , 1986, The American journal of medicine.
[272] J. Pizzuto,et al. Therapeutic experience on 934 adults with idiopathic thrombocytopenic purpura: Multicentric Trial of the Cooperative Latin American group on Hemostasis and Thrombosis. , 1984, Blood.
[273] R. Mylvaganam,et al. Slow infusion of vinca alkaloids in the treatment of idiopathic thrombocytopenic purpura. , 1984, Annals of internal medicine.
[274] M. Mant,et al. Severe thrombocytopenia probably due to acute folic acid deficiency , 1979, Critical care medicine.
[275] C. Kitchens. Amelioration of endothelial abnormalities by prednisone in experimental thrombocytopenia in the rabbit. , 1977, The Journal of clinical investigation.
[276] G. Masera,et al. More on vincristine in treatment of ITP in children. , 1977, The New England journal of medicine.
[277] L. Weiss,et al. Ultrastructural changes of endothelium associated with thrombocytopenia. , 1975, Blood.
[278] Y. Ahn,et al. Vincristine therapy of idiopathic and secondary thrombocytopenias. , 1974, The New England journal of medicine.
[279] S. Lewis. British Committee for Standards in Haematology , 1969 .
[280] N. Shaheen,et al. Splenectomy vs. rituximab as a second-line therapy in immune thrombocytopenic purpura: a single center experience , 2017, International Journal of Hematology.
[281] Sung-Soo Yoon,et al. Multicenter, prospective study to evaluate the efficacy of biweekly romiplostim administration in patients with immune thrombocytopenia , 2015, International Journal of Hematology.
[282] V. Mishra,et al. Vitamin B12 and Vitamin D Deficiencies: An Unusual Cause of Fever, Severe Hemolytic Anemia and Thrombocytopenia , 2015, Journal of family medicine and primary care.
[283] M. Kurokawa,et al. Comparison between pulsed high-dose dexamethasone and daily corticosteroid therapy for adult primary immune thrombocytopenia: a retrospective study. , 2012, Internal medicine.
[284] S. Alkindi,et al. Balla lupus erythematosus Successful treatment of severe thrombocytopenia with romiplostim in a pregnant patient with systemic , 2012 .
[285] M. Sanz,et al. Analysis of EQ-5D scores from two phase 3 clinical trials of romiplostim in the treatment of immune thrombocytopenia (ITP). , 2011, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[286] P. Kyrle,et al. The course of severe autoimmune thrombocytopenia in patients not undergoing splenectomy. , 2006, Haematologica.
[287] Y. Abe,et al. A simple technique to determine thrombopoiesis level using immature platelet fraction (IPF). , 2006, Thrombosis research.
[288] P. Bierling,et al. Assessment of a therapeutic strategy for adults with severe autoimmune thrombocytopenic purpura based on a bleeding score rather than platelet count. , 2005, Haematologica.
[289] V. M. Malikov,et al. Vinca alkaloids , 2004, Chemistry of Natural Compounds.
[290] S. Asano,et al. Clinical usefulness of vinca alkaloid slow infusion in the treatment of chronic refractory idiopathic thrombocytopenic purpura: a multicenter cooperative study. , 1990, Nihon Ketsueki Gakkai zasshi : journal of Japan Haematological Society.
[291] N. Shulman,et al. The role of the reticuloendothelial system in the pathogenesis of idiopathic thrombocytopenic purpura. , 1965, Transactions of the Association of American Physicians.
[292] Andrews Hl,et al. The role of the reticuloendothelial system in the pathogenesis of idiopathic thrombocytopenic purpura. , 1965, Transactions of the Association of American Physicians.